TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05509621

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The Effect of left lateral Position on Physiological Parameters in Mechanically Ventilated Preterm Newborns
Description: Preterm neonates who receive mechanical ventilation support and meet the study criteria will be provided with daily routine nursing care. Afterward, when it is time for positioning, the infant will be randomly placed in positions assigned according to the randomization. After positioning, data will not be collected for the first 30 minutes of each positioning in order to ensure the stability of the neonate. Starting from the 30th minute, the heart rate and oxygen saturation of the preterm neonate will be checked on the monitor at 15-minute intervals over the course of 90 minutes, and the respiratory rate will be counted and recorded for 1 minute by the researcher. For each position, the procedures will be repeated in the same way and the values will be recorded.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The Effect of right lateral Position on Physiological Parameters in Mechanically Ventilated Preterm Newborns
Description: Preterm neonates who receive mechanical ventilation support and meet the study criteria will be provided with daily routine nursing care. Afterward, when it is time for positioning, the infant will be randomly placed in positions assigned according to the randomization. After positioning, data will not be collected for the first 30 minutes of each positioning in order to ensure the stability of the neonate. Starting from the 30th minute, the heart rate and oxygen saturation of the preterm neonate will be checked on the monitor at 15-minute intervals over the course of 90 minutes, and the respiratory rate will be counted and recorded for 1 minute by the researcher. For each position, the procedures will be repeated in the same way and the values will be recorded.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The Effect of Quarter prone Position on Physiological Parameters in Mechanically Ventilated Preterm Newborns
Description: Preterm neonates who receive mechanical ventilation support and meet the study criteria will be provided with daily routine nursing care. Afterward, when it is time for positioning, the infant will be randomly placed in positions assigned according to the randomization. After positioning, data will not be collected for the first 30 minutes of each positioning in order to ensure the stability of the neonate. Starting from the 30th minute, the heart rate and oxygen saturation of the preterm neonate will be checked on the monitor at 15-minute intervals over the course of 90 minutes, and the respiratory rate will be counted and recorded for 1 minute by the researcher. For each position, the procedures will be repeated in the same way and the values will be recorded.
Study: NCT06512233

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LMW Heparin 5000 U/ML-Aspirin 75 MG
Description: Arm 1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LMW Heparin 5000 U/ML
Description: Arm 2
Study: NCT05990439

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Baby-Feed
Description: The Baby-Feed web application was developed by the researchers of this application at Florida International University. It was designed based on a validated infant food frequency questionnaire (FFQ) developed by our group. The Social Cognitive Theory (SCT) and the Health Self-Empowerment Theory (HSET) were used in the development of the different components. The main intervention component is showing automatic results on how well parents are feeding their infants, upon completion of the infant FFQ, showing results on which food groups are consumed at the recommended level, which are consumed above and which are consumed below. It also shows a growth chart showing how the baby is progressing when they add their baby's weight and length. The website also includes a tracking system with short questions asking about their weekly progress and the recommendations to review frequently, if needed.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Limited access to the Baby-Feed web application
Description: Limited access to the Baby-Feed web application, with only the options of completing the FFQ and inputing their baby's weight and length.
Study: NCT05983406

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Doppler investigation
Description: Doppler investigation
Study: NCT06171178

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1012
Description: Intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1012
Description: Intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1012
Description: Intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1012
Description: Intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1012
Description: Intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion
Study: NCT04764942

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO
Study: NCT04775043

Intervention type: DIAGNOSTIC_TEST
Intervention: HFRDIS questionnaire completion
Description: HFRDIS Questionnaire (Hot Flash Related Daily Interference Scale) completion
Study: NCT06302283

Intervention type: OTHER
Intervention: Survey
Description: Survey (online or paper) on caregiving burden and bereavement
Study: NCT05621980

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Actuated Virtual Keyboard (AVK) system
Description: The participant controls an avatar hand by the movement of their own digits. Each avatar digit corresponds to a given virtual key. Sufficient digit flexion results in playing of that key, with visual and auditory feedback of key strike. Participants will wear a soft exoskeleton, the PneuGlove, with embedded bend sensors to provide real-time measurement of digit flexion. Pneumatic resistance to flexion can be applied to each digit independently, along with extension assistance, through air chambers running through the glove. The FES is intended to assist finger flexion by activating extrinsic finger flexor muscles. A high-density 2×8 stimulation electrode grid will be placed over the median and ulnar nerves at the medial side of the upper arm. The stimulator can deliver electrical stimulation to any pair of electrodes. At the beginning of each session, the investigators will identify the electrode pairs which best produce flexion of each digit with minimal discomfort.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Occupational Therapy (OT)
Description: Traditional occupational therapy training sessions.
Study: NCT05919056

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Frequent and automatic cardiovascular risk assessment
Description: The 10-year cardiovascular risk scores using the 2019 World Health Organization (WHO) laboratory-based risk charts will be automatically calculated using the latest health information on an EHR-based system per month.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dynamic risk monitoring
Description: High-risk individuals will be reassessed by the Dynamic Risk-based Early wArning and Monitoring (DREAM) system to obtain the short-term risk. The DREAM system will send a text message about advice to the high-risk individual every month. The text message includes information on the health status (e.g., current cardiovascular risk, level of blood pressure and lipid) and real-time warning messages (e.g., high short-term risk).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Regular GP visits
Description: The general practitioners will communicate with the participants based on the information automatically generated from the DREAM system every three months: each participant's cardiovascular risk score, health status (e.g., diabetes mellitus and/or hypertension), and Chinese guidelines-based recommendations (e.g., for the management of dyslipidemia, to provide clear treatment targets for high-risk participants).
Study: NCT05420454

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: 75 mg/m2, d1, q3w,6 cycles
Study: NCT05420454

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: AUC 6, d1, q3w ,6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC 6, d1, q3w ,6 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: starting dose 8 mg/kg, maintenance dose 6 mg/kg, d1, q3w ,6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: starting dose 8 mg/kg, maintenance dose 6 mg/kg, d1, q3w ,6 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pertuzumab
Description: starting dose of 840 mg, maintenance dose of 420 mg, d1, q3w,6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: starting dose of 840 mg, maintenance dose of 420 mg, d1, q3w,6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab paclitaxel
Description: 220 mg/m2, d1, q3w,6 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epirubicin
Description: 90 mg/m2,d1, q3w × 4 cycles,followed by docetaxel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: 600 mg/m2, d1, q3w ,4 cycles,followed by docetaxel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: 100 mg/m2, d1, q3w × 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: 90 mg/m2,d1, q2w × 4 cycles,followed by nab-paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 600 mg/m2, d1, q2w × 4 cycles followed by nab-paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab paclitaxel
Description: 125 mg/m2, d1,8,15, q3w× 4 cycles
Study: NCT04764942

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Given PO
Study: NCT05461898

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Inpatient Rehabilitation
Description: Standard inpatient rehabilitation program with a interdisciplinary team that included a physiotherapist who ensured muscle strength, balance, aerobic and functional training, an occupational therapist who provided training of basic and instrumental activities of daily living and education of energy conservation techniques and a a speech and language therapist for swallowing training.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inpatient Rehabilitation
Description: Standard inpatient rehabilitation program with a interdisciplinary team that included a physiotherapist who ensured muscle strength, balance, aerobic and functional training, an occupational therapist who provided training of basic and instrumental activities of daily living and education of energy conservation techniques and a a speech and language therapist for swallowing training.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training
Description: Inspiratory muscle training protocol during 6 weeks with a electronic-controlled valve device
Study: NCT00670384

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Standardized Allergenic Extract, Short Ragweed (Ambrosia artemisiifolia)
Description: Sublingual drops

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Standardized Allergenic Extract, Short Ragweed (Ambrosia artemisiifolia)
Description: Sublingual drops

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sublingual drops
Study: NCT04764942

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT06235541

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GENA-104A16
Description: GENA-104A16 is administered as a 1 hour (h) \[-5 minutes and +60 minutes , i.e., 55-120 minutes as window time\] as intravenous (IV) infusion on q2w.
Study: NCT04764942

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: X-Ray Imaging
Description: Undergo x-ray imaging

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: X-Ray Imaging
Description: Undergo x-ray imaging

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo PET/CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo PET/CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy and aspiration

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy and aspiration
Study: NCT06208176

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: High-definition transcranial direct current (HD-tDCS), active condition
Description: Patients will receive 20 sessions of active HD-tDCS for a duration of 20min. Sessions will be delivered twice-daily over 2 weeks on the 5 consecutive working days. The number of electrodes used, electrode placement on the scalp (based on EEG 10/10), and the individual currents that need to be injected from each electrode will be determined based on the brain networks identified as involved in their hallucinations during a fMRI acquisition performed at baseline, and computed using a neurotargeting software that allows determining optimal electrode montages for achieving maximal brain current flow in the targeted brain region.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: High-definition transcranial direct current (HD-tDCS), sham condition
Description: Participants will receive 20 sessions of sham HD-tDCS, which will be delivered following the same procedures as active HD-tDCS. However, stimulation will only be administered in the initial 30 seconds of the 20-minute period, with no further stimulation during the remaining duration. This approach aims to replicate the tingling sensation commonly associated with active stimulation.
Study: NCT05333471

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MTP 101-LF
Description: Each unit of MTP-101-LF contains approximately 35 mL of fecal transplant product. Participants will receive approximately 32 mL via colonoscopy.
Study: NCT06742970

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Telematic intervention
Description: Telematic intervention will be performed by a specialized company hired by the investigational team. Trained nurses will contact patients assigned to the intervention groups by videocalls at weeks 1,3,5,7,9,11 and 12 after the admission. The specialized nurses will supervise the exercise program sessions (based on an adaptation of he VIVI FRAIL program), correcting potential mistakes and recommending the optimal way for performing the training program. Patients will take a 200 ml dose of hyperproteic, hypercaloric nutrition supplements daily one hour after performing the exercise session. Information about the optimal diet adapted to the clinical profile of patients will be also provided. Additionally, health information about the disease, the importance of adherence to treatments and recommendations and the best measures for controling cardiovascular risk factors, comorbidities and avoiding clinical complications will be also provided
Study: NCT06742385

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MedicWise
Description: * Both arms are equipped with the application, data are collected via the application and telemonitoring with alerts to the care team are activated in the active telemonitoring arm.~* Data are collected in both arms at baseline, M3, M6, M9 and M12~* Each center defines who handles alerts internally (physicians, IBD nurses, others, etc.) according to its internal organization. The application does not impose an internal operation.~* the alert thresholds are identical and fixed for all centers during the study. Within the framework of the study, alerts are defined according to the study's modalities but cannot be modified by the centers.~* Participating sites will have no obligation to respond to alerts.~* Randomization will be stratified by centers and by diseases (Crohn and UC) with unbalanced blocks of randomization
Study: NCT06742164

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ivabradine 5mg Tab
Description: Ivabradine (5 mg twice daily) orally or via nasogastric tube

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: control
Description: Patients didn't receive Ivabradine .
Study: NCT06742411

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XELOX+Sintilimab+HBOT
Description: Patients will receive the XELOX regimen, consisting of oxaliplatin (130 mg/m² IV on Day 1) and capecitabine (1000 mg/m² orally twice daily for 14 days, repeated every 3 weeks), combined with sintilimab (200 mg IV on Day 1 every 3 weeks) and hyperbaric oxygen therapy (HBOT) administered alongside the XELOX regimen. Treatment will be administered for 4 to 6 cycles.~Following the initial treatment phase, patients will be evaluated for response. If disease progression is observed, patients will exit the study and receive subsequent treatments as deemed appropriate. For patients with stable disease or a response to therapy, maintenance treatment with capecitabine and sintilimab will continue until the occurrence of a study endpoint or other specified criteria.
Study: NCT06741449

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: keystone flap
Description: facio-cutaneous flap used to cover the defect after removal of the disease

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: lay open
Description: after removal of the disease, the wound is left open to heal by granulation tissue
Study: NCT06741501

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: C Single Flap Plasty Reconstruction
Description: 1. C-shaped flap creation: A 3.0 cm wide by 3.5 cm high C-shaped flap is marked on the anterior gastric wall, 1.5-2.5 cm distal to the stomach transection line. The flap is created by carefully separating the submucosa from the muscular propria using an electric scalpel, forming a left-opening flap. This flap will later be used to cover the anastomotic site. 2. Esophagogastric anastomosis: The esophagus and stomach are anastomosed intracorporeally. After continuous suturing of the posterior esophageal wall to the remnant stomach, the common opening between the esophagus and the stomach is closed. 3. Flap coverage: After anastomosis, the C-shaped flap is sutured over the anastomotic site, reinforcing it by covering both the esophageal stump and the gastric window, which helps prevent complications like leakage or reflux.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Normal Reconstruction
Description: 1. Preparation of the Remnant Stomach and Esophagus: After the resection of the proximal stomach, the remaining stomach is prepared for direct anastomosis with the esophagus. The esophageal stump and gastric stump are aligned, typically without additional modifications to the gastric wall. 2. End-to-End or End-to-Side Anastomosis: The esophagus is directly connected to the remnant stomach, either in an end-to-end or end-to-side fashion, using a stapler or manual suturing techniques.
Study: NCT06742229

Intervention type: DEVICE
Group type: OTHER
Intervention: Research Ultrasound scan
Description: Both the study groups will be asked to undergo a research scan performed by an FDA approved ultrasound device

Intervention type: DEVICE
Group type: OTHER
Intervention: Research Ultrasound scan
Description: Both the study groups will be asked to undergo a research scan performed by an FDA approved ultrasound device
Study: NCT06742567

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban 2.5 MG PO BID
Description: Patients randomized to the treatment arm will be given Apixaban 2.5 mg twice daily and DAPT (aspirin (75 mg) + clopidogrel (75 mg)) for four weeks in addition to other guideline directed medical therapy (GDMT). After 4 weeks, treatment group will be switched to DAPT.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Control (Standard treatment)
Description: DAPT plus guideline directed medical therapy
Study: NCT06742775

Intervention type: OTHER
Intervention: physiological signal acquisitions
Description: Subjects will be fitted with non-intrusive devices. In a semi-recumbent position, they will be asked to perform~* 10 minutes of resting breathing~* 10 cycles consisting of a 20-second apnea, to be performed at the end of inspiration, and 1 minute 40 of breathing (100 seconds).~This single participation session will last a total of one hour for the volunteer (equipment, recording, de-equipping), including 30 minutes of acquisition.

Intervention type: OTHER
Intervention: physiological signal acquisitions
Description: Subjects will be fitted with non-intrusive devices. In a semi-recumbent position, they will be asked to perform~* 10 minutes of resting breathing~* 10 cycles consisting of a 20-second apnea, to be performed at the end of inspiration, and 1 minute 40 of breathing (100 seconds).~This single participation session will last a total of one hour for the volunteer (equipment, recording, de-equipping), including 30 minutes of acquisition.

Intervention type: OTHER
Intervention: physiological signal acquisitions
Description: Subjects will be fitted with non-intrusive devices. In a semi-recumbent position, they will be asked to perform~* 10 minutes of resting breathing~* 10 cycles consisting of a 20-second apnea, to be performed at the end of inspiration, and 1 minute 40 of breathing (100 seconds).~This single participation session will last a total of one hour for the volunteer (equipment, recording, de-equipping), including 30 minutes of acquisition.